PipelineRSSToday
Companies join forces to speed production of 1-time treatment for FSHD
Two companies, Epicrispr Biotechnologies and Forge Biologics, are working together to make EPI-321, a new one-time treatment for facioscapulohumeral muscular dystrophy (FSHD). FSHD is a rare muscle disease that causes progressive weakness. The treatment works by using epigenetics—a way to turn off genes without changing their DNA—to stop the abnormal gene that causes FSHD.
WHY IT MATTERSThis partnership could accelerate production of EPI-321, potentially bringing a one-time treatment option closer to FSHD patients who currently have limited approved therapies.